e-ISSN: Pending
Negative / Null Result ReportOpen accessBiochemistry, Genetics and Molecular Biology· cited by 119

E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group

Roisín M. Connolly; Fengmin Zhao; Kathy D. Miller; Min-Jung Lee; Richard Piekarz; Karen L. Smith; Ursa Brown‐Glaberman; Jennifer S. Winn · 2021 · Journal of Clinical Oncology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract (excerpt)

PURPOSE Endocrine therapy resistance in advanced breast cancer remains a significant clinical problem that may be overcome with the use of histone deacetylase inhibitors such as entinostat. The ENCORE301 phase II study reported improvement…

Excerpt shown for reference under fair use — read the full paper at the publisher.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1200/jco.21.00944